3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
14
Glioblastoma
10
Pancreatic Neoplasms
9
Breast Neoplasms
9
Neoplasms
8
Glioma
8
Prostatic Neoplasms
5
Colonic Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
4
Astrocytoma
4
Oligodendroglioma
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Osteosarcoma
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled